Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis
暂无分享,去创建一个
K. Lunnon | L. Hubbard | I. Castanho | E. Pishva | Rebecca G. Smith | B. Creese | Adam R. Smith | N. Williams | Joshua Harvey | Luke Stephen Weymouth | Kate Bresner
[1] P. Passmore,et al. Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential , 2022, Communications Biology.
[2] J. Marchini,et al. Universal clinical Parkinson’s disease axes identify a major influence of neuroinflammation , 2022, Genome Medicine.
[3] K. Jellinger. The pathobiological basis of depression in Parkinson disease: challenges and outlooks , 2022, Journal of Neural Transmission.
[4] L. Guan,et al. Application of Neurotoxin-Induced Animal Models in the Study of Parkinson’s Disease-Related Depression: Profile and Proposal , 2022, Frontiers in Aging Neuroscience.
[5] Syeda Sana Samar,et al. Prodromal depression and subsequent risk of developing Parkinson's disease: a systematic review with meta-analysis. , 2022, Neurodegenerative disease management.
[6] Evan Z. Macosko,et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease , 2022, Nature Neuroscience.
[7] Alan J. Thomas,et al. Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology , 2021, Nature Communications.
[8] Parkinson disease-associated cognitive impairment , 2021, Nature Reviews Disease Primers.
[9] R. Barker,et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.
[10] J. Hardy,et al. Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets , 2021, JAMA neurology.
[11] K. Lunnon,et al. Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Histone Modifications in Dementia , 2020, Current Genetic Medicine Reports.
[12] Zina M. Ibrahim,et al. An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene , 2020, Neurobiology of Aging.
[13] J. Jankovic,et al. Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] Wenda Xue,et al. Crocin Reverses Depression-Like Behavior in Parkinson Disease Mice via VTA-mPFC Pathway , 2020, Molecular Neurobiology.
[15] Alan J. Thomas,et al. A meta-analysis of epigenome-wide association studies in Alzheimer’s disease highlights novel differentially methylated loci across cortex , 2020, Nature Communications.
[16] E. Henderson,et al. Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment , 2020, BJPsych Advances.
[17] J. Mill,et al. Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex , 2020, Neurobiology of Aging.
[18] Juan I. Young,et al. Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease , 2019, Neurology: Genetics.
[19] S. Horvath,et al. Longitudinal Epigenome-Wide Methylation Study of Cognitive Decline and Motor Progression in Parkinson's Disease. , 2019, Journal of Parkinson's disease.
[20] Alan J. Thomas,et al. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders , 2019, Brain pathology.
[21] Yoshihiro Kokubo,et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.
[22] R. Barker,et al. The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.
[23] D. Aarsland,et al. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses , 2018, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[24] Yadong Wang,et al. A framework for analyzing DNA methylation data from Illumina Infinium HumanMethylation450 BeadChip , 2018, BMC Bioinformatics.
[25] M. Kuijf,et al. Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis , 2016, Movement disorders : official journal of the Movement Disorder Society.
[26] C. Allis,et al. The molecular hallmarks of epigenetic control , 2016, Nature Reviews Genetics.
[27] Seth G. N. Grant,et al. Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type Enrichment , 2016, Front. Neurosci..
[28] A. Verkhratsky,et al. Decrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson’s disease , 2015, Front. Cell. Neurosci..
[29] N. Kandiah,et al. Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. , 2015, Parkinsonism & related disorders.
[30] A. Nordström,et al. Depression and subsequent risk of Parkinson disease , 2015, Neurology.
[31] Edo Richard,et al. Apathy in Parkinson's disease: A systematic review and meta‐analysis , 2015, Movement disorders : official journal of the Movement Disorder Society.
[32] D. Bennett,et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease , 2014, Nature Neuroscience.
[33] Ruth Pidsley,et al. A data-driven approach to preprocessing Illumina 450K methylation array data , 2013, BMC Genomics.
[34] J. Mill,et al. A data-driven approach to preprocessing Illumina 450K methylation array data , 2013, BMC Genomics.
[35] L. Coin,et al. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[36] Matko Bosnjak,et al. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.
[37] Guido Alves,et al. Epidemiology of psychosis in Parkinson's disease , 2010, Journal of the Neurological Sciences.
[38] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[39] J. Jankovic. Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[40] H. Braak,et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.
[41] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[42] J A Knottnerus,et al. Increased risk of Parkinson’s disease after depression: A retrospective cohort study , 2002, Neurology.
[43] D. Aarsland,et al. Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study , 2000, Journal of the American Geriatrics Society.
[44] J. Cummings,et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.
[45] A. Kurz,et al. Predictors of nursing home placement in patients with alzheimer's disease , 1993 .
[46] Dag Aarsland,et al. Depression in Parkinson disease—epidemiology, mechanisms and management , 2011, Nature Reviews Neurology.
[47] V. Haroutunian,et al. The neuropathological basis for depression in Parkinson's disease. , 2009, Parkinsonism & related disorders.